In its lawsuit, Pfizer said the structure of Novo Nordisk’s offer for Metsera—a complicated two-step process—is intended to circumvent antitrust review.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”